ITPKA1 Promotes Growth, Migration and Invasion of Renal Cell Carcinoma via Activation of mTOR Signaling Pathway

References

• Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387:894–906. doi:10.1016/S0140-6736(15)00046-X26318520
   PubMed Web of Science ®Google Scholar
• Osawa T, Takeuchi A, Kojima T, et al. Overview of current and future systemic therapy for metastatic renal cell carcinoma. Jpn J Clin Oncol. 2019;49:395–403. doi:10.1093/jjco/hyz01330722031
   PubMed Web of Science ®Google Scholar
• Gustin P, Yossi S, Lafont, G M, et al. Use of chemotherapy and radiotherapy in the treatment of urothelial carcinoma of the upper urinary tract. Cancer Radiother. 2015;19:120–126. doi:10.1016/j.canrad.2014.11.01225770883
   PubMedGoogle Scholar
• Poletto V, Rosti V, Biggiogera M, et al. The role of endothelial colony forming cells in kidney cancer’s pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: a speculative review. Crit Rev Oncol Hematol. 2018;132:89–99. doi:10.1016/j.critrevonc.2018.09.00530447930
   PubMed Web of Science ®Google Scholar
• Calvo E, Porta C, Grünwald V, et al. The current and evolving landscape of first-line treatments for advanced renal cell carcinoma. Oncologist. 2019;24:338–348. doi:10.1634/theoncologist.2018-026730158285
   PubMed Web of Science ®Google Scholar
• Ghidini M, Petrelli F, Ghidini A, et al. Clinical development of mTOR inhibitors for renal cancer. Expert Opin Investig Drugs. 2017;26:1229–1237. doi:10.1080/13543784.2017.1384813
   PubMed Web of Science ®Google Scholar
• Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012;104:93–113. doi:10.1093/jnci/djr51122235142
   PubMed Web of Science ®Google Scholar
• Bukowski RM. Temsirolimus: a safety and efficacy review. Expert Opin Drug Saf. 2012;11:861–879. doi:10.1517/14740338.2012.71334422861825
   PubMed Web of Science ®Google Scholar
• Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am. 2011;25:835–852. doi:10.1016/j.hoc.2011.04.00821763970
   PubMed Web of Science ®Google Scholar
• Kim IH, Park SK, Hong ST, et al. Inositol 1,4,5-trisphosphate 3-kinase a functions as a scaffold for synaptic Rac signaling. J Neurosci. 2009;29:14039–14049. doi:10.1523/JNEUROSCI.2483-09.200919890013
   PubMed Web of Science ®Google Scholar
• Schröder D, Rehbach C, Seyffarth C, et al. Identification of a new membrane-permeable inhibitor against inositol-1, 4, 5-trisphosphate-3-kinase A. Biochem Biophys Res Commun. 2013;20:228–234. doi:10.1016/j.bbrc.2013.08.053
   Google Scholar
• Windhorst S, Song K, Gazdar AF. Inositol-1,4,5-trisphosphate 3-kinase-A (ITPKA) is frequently over-expressed and functions as an oncogene in several tumor types. Biochem Pharmacol. 2017;137:1–9. doi:10.1016/j.bcp.2017.03.02328377279
   PubMed Web of Science ®Google Scholar
• Dominik S, Klaus T, Beatriz G, et al. The new InsP3Kinase inhibitor BIP-4 is competitive to InsP3 and blocks proliferation and adhesion of lung cancer cells. Biochem Pharmacol. 2015;96:143–150. doi:10.1016/j.bcp.2015.05.00425986882
   PubMed Web of Science ®Google Scholar
• Chai D, Shan H, Wang G, et al. AIM2 is a potential therapeutic target in human renal carcinoma and suppresses its invasion and metastasis via enhancing autophagy induction. Exp Cell Res. 2018;370:561–570. doi:10.1016/j.yexcr.2018.07.02130031129
   PubMed Web of Science ®Google Scholar
• Lee DJ, Xylinas E, Rieken M, et al. Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. Eur Urol. 2014;66:379–385. doi:10.1016/j.eururo.2013.12.00824388440
   PubMed Web of Science ®Google Scholar
• Åström M, Tajeddinn W, Karlsson MG, et al. Cytokine measurements for diagnosing and characterizing leukemoid reactions and immunohistochemical validation of a granulocyte colony-stimulating factor and CXCL8-producing renal cell carcinoma. Biomark Insights. 2018;13:1177271918792246. doi:10.1177/117727191879224630147294
   PubMed Web of Science ®Google Scholar
• Cui XF, Cui XG, Leng N. Overexpression of interleukin-20 receptor subunit beta (IL20RB) correlates with cell proliferation, invasion and migration enhancement and poor prognosis in papillary renal cell carcinoma. J Toxicol Pathol. 2019;32:245–251. doi:10.1293/tox.2019-001731719751
   PubMed Web of Science ®Google Scholar
• Windhorst S, Kalinina T, Schmid K, et al. Functional role of inositol-1,4,5-trisphosphate-3-kinase-A for motility of malignant transformed cells. Int J Cancer. 2011;129:1300–1309. doi:10.1002/ijc.2578221792881
   PubMed Web of Science ®Google Scholar
• Wang YW, Ma X, Zhang YA, et al. ITPKA gene body methylation regulates gene expression and serves as an early diagnostic marker in lung and other cancers. J Thorac Oncol. 2016;11:1469–1481. doi:10.1016/j.jtho.2016.05.01027234602
   PubMed Web of Science ®Google Scholar
• Zhou GR, Fan ZH, Zhu W, et al. TFAP2A induced ITPKA serves as an oncogene and interacts with DBN1 in lung adenocarcinoma. Int J Biol Sci. 2020;16:504–514. doi:10.7150/ijbs.4043532015686
   PubMed Web of Science ®Google Scholar
• Li J, Zhu YH, Huang P, et al. ITPKA expression is a novel prognostic factor in hepatocellular carcinoma. Diagn Pathol. 2015;10:136. doi:10.1186/s13000-015-0374-126249031
   PubMed Web of Science ®Google Scholar
• Ashour DJ, Pelka B, Jaaks P, et al. The catalytic domain of inositol-1, 4, 5-trisphosphate 3-kinase-a contributes to ITPKA-induced modulation of F-actin. Cytoskeleton (Hoboken). 2015;72:93–100. doi:10.1002/cm.2120825620569
   PubMed Web of Science ®Google Scholar
• Fumarola C, Bonelli MA, Petronini PG, et al. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol. 2014;90:197–207. doi:10.1016/j.bcp.2014.05.01124863259
   PubMed Web of Science ®Google Scholar
• Wang XW, Zhang YJ. Targeting mTOR network in colorectal cancer therapy. World J Gastroenterol. 2014;20:4178–4188. doi:10.3748/wjg.v20.i15.417824764656
   PubMed Web of Science ®Google Scholar
• Sharma VR, Gupta GK, Sharma AK, et al. PI3K/Akt/mTOR intracellular pathway and breast cancer: factors, mechanism and regulation. Curr Pharm Des. 2017;23:1633–1638. doi:10.2174/138161282366616111612521827848885
   PubMed Web of Science ®Google Scholar
• Kumar A, Kumari N, Gupta V, et al. Renal cell carcinoma: molecular aspects. Indian J Clin Biochem. 2018;33:246–254. doi:10.1007/s12291-017-0713-y30072823
   PubMed Web of Science ®Google Scholar
• Kajiwara M, Masuda S. Role of mTOR inhibitors in kidney disease. Int J Mol Sci. 2016;17:975. doi:10.3390/ijms17060975
   PubMed Web of Science ®Google Scholar
• Pal SK, Quinn DI. Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev. 2013;39:709–719. doi:10.1016/j.ctrv.2012.12.01523433636
   PubMed Web of Science ®Google Scholar
• Toschi A, Lee E, Xu L, et al. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol. 2009;29:1411–1420. doi:10.1128/MCB.00782-0819114562
   PubMed Web of Science ®Google Scholar